169 related articles for article (PubMed ID: 30535445)
41. MiR-141 promotes cell proliferation and invasion in non-small cell lung cancer by targeting KLF9.
Kong YJ; Tan XX; Zhang Y; He QJ; Zhao L; Meng Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10370-10378. PubMed ID: 31841191
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification.
Samejima J; Yokose T; Ito H; Nakayama H; Nagashima T; Suzuki M; Hamanaka R; Yamada K; Masuda M
Lung Cancer; 2019 Nov; 137():144-148. PubMed ID: 31593845
[TBL] [Abstract][Full Text] [Related]
43. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL
Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983
[TBL] [Abstract][Full Text] [Related]
44. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
45. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
46. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
48. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
49. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
50. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
51. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas.
Yang SH; Baek HA; Lee HJ; Park HS; Jang KY; Kang MJ; Lee DG; Lee YC; Moon WS; Chung MJ
Oncol Rep; 2010 Aug; 24(2):311-9. PubMed ID: 20596615
[TBL] [Abstract][Full Text] [Related]
52. DNA hypermethylation of the ZNF132 gene participates in the clinicopathological aggressiveness of 'pan-negative'-type lung adenocarcinomas.
Hamada K; Tian Y; Fujimoto M; Takahashi Y; Kohno T; Tsuta K; Watanabe SI; Yoshida T; Asamura H; Kanai Y; Arai E
Carcinogenesis; 2021 Feb; 42(2):169-179. PubMed ID: 33152763
[TBL] [Abstract][Full Text] [Related]
53. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
[TBL] [Abstract][Full Text] [Related]
54. Pathobiological implications of MUC4 in non-small-cell lung cancer.
Majhi PD; Lakshmanan I; Ponnusamy MP; Jain M; Das S; Kaur S; Shimizu ST; West WW; Johansson SL; Smith LM; Yu F; Rolle CE; Sharma P; Carey GB; Batra SK; Ganti AK
J Thorac Oncol; 2013 Apr; 8(4):398-407. PubMed ID: 23370366
[TBL] [Abstract][Full Text] [Related]
55. High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.
Zhai X; Xu L; Zhang S; Zhu H; Mao G; Huang J
Oncotarget; 2016 Jan; 7(4):4871-81. PubMed ID: 26717042
[TBL] [Abstract][Full Text] [Related]
56. Correlation of integrin alpha 7 with clinicopathological characteristics and survival profiles, as well as its regulatory role in cell proliferation, apoptosis, and stemness in non-small-cell lung cancer.
Xia D; Chen B; Yang X
J Clin Lab Anal; 2019 Oct; 33(8):e22973. PubMed ID: 31418948
[TBL] [Abstract][Full Text] [Related]
57. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer.
Horne ZD; Jack R; Gray ZT; Siegfried JM; Wilson DO; Yousem SA; Nason KS; Landreneau RJ; Luketich JD; Schuchert MJ
J Surg Res; 2011 Nov; 171(1):1-5. PubMed ID: 21571304
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-130a targeting hypoxia-inducible factor 1 alpha suppresses cell metastasis and Warburg effect of NSCLC cells under hypoxia.
Shi J; Wang H; Feng W; Huang S; An J; Qiu Y; Wu K
Life Sci; 2020 Aug; 255():117826. PubMed ID: 32450163
[TBL] [Abstract][Full Text] [Related]
59. Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma.
Zhan ZY; Zhong LX; Feng M; Wang JF; Liu DB; Xiong JP
Int J Clin Exp Pathol; 2015; 8(5):5080-8. PubMed ID: 26191202
[TBL] [Abstract][Full Text] [Related]
60. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
